The Latest Breaking News from Piper Sandler

Evolent Health 'Notification Award' Removes $82M Overhang, Notes Piper Sandler

In an SEC filing, Cook County named Evolent Health Inc (NYSE:EVH) the sole third-party administrator for CountyCare Health Plan from fiscal 2023 through fiscal 2025. Piper Sandler analyst Jessica Tassan notes that the award extends a contract Evolent has held since fiscal 2018 to provide administrative simplification services to support CountyCare's 425,000 Medicaid…

Benzinga · Mar 7, 2022

Analysts Move To Sidelines On Vicarious Surgical After Regulatory Update

Piper Sandler has downgraded Vicarious Surgical Inc (NASDAQ:RBOT) to Neutral from Overweight with a price target of $7, down from $16, below expected Q4 results.  A majority of the earnings call focused on the Company's regulatory update. Vicarious announced its plans to pursue a De Novo FDA pathway, including a pre-market study, for its…

Benzinga · Mar 4, 2022

Analysts Cut Price Target On Aziyo Biologics As Q4 Earnings Fall Short Of Expectations

Aziyo Biologics  Inc (NASDAQ:AZYO) Q4 FY21 sales decreased 13% to $10.9 million, missing the consensus of $11.06 million. Excluding the contribution of FiberCel sales, which the product's distributor discontinued in Q2 of 2021, Q4 sales increased 6% Y/Y. The 510(k) application for CanGaroo RM, the Company's next-generation envelope, remains on track for submission…

Benzinga · Mar 4, 2022

Analysts Continue To See Sharp Upside In Sprout Social Post Q4 Results

Analysts cut their price targets on Sprout Social Inc (NASDAQ:SPT) post Q4 results. Needham analyst Scott Berg lowered the price target to $75 from $160 (37% upside) given the significant multiple compression across high growth software but kept a Buy.  The company's Q4 results were "impressive," highlighted by the acceleration of upmarket demand, record large…

Benzinga · Feb 23, 2022

Piper Sandler Upgrades Marathon Oil After Strong Management Message

Marathon Oil Corporation (NYSE: MRO) expects to return up to $3.1 billion to shareholders in 2022, which equates to around 20% of its shares outstanding, according to Piper Sandler.

Benzinga · Feb 23, 2022

Read How Analysts Reacted To Aspen Aerogels' Q4 Results

H.C. Wainwright analyst Amit Dayal lowered the price target on Aspen Aerogels Inc (NYSE:ASPN) to $45 (an upside of 57.6%) from $65 and maintained a Buy rating on the shares.  The analyst cites the company's updated outlook stemming from plans for its thermal runaway expansion for the target drop.  Though Aspen's mid-term expectation of hitting…

Benzinga · Feb 18, 2022

Read How Analysts Reacted To Alteryx's Q4 Results

Analysts had mixed opinions on Alteryx Inc (NYSE:AYX) post Q4 beat. Alteryx is a software company that provides self-service data analytics software. Oppenheimer analyst Ittai Kidron lowered the firm's price target on Alteryx to $85 from $105 (62.9% upside) to reflect multiple realignments while keeping an Outperform rating on the shares.  The analyst notes Alteryx's Q4…

Benzinga · Feb 16, 2022

Here's Why Piper Sandler Is Optimistic On Nvidia

Piper Sandler analyst Harsh Kumar reiterated an Overweight rating and $350 price target on NVIDIA Corp (NASDAQ:NVDA). Nvidia could be a big winner this earnings season, with profits driven by solid performance in the chip maker's gaming and data center businesses, Kumar said. "We are looking for a significant beat and raise when the company…

Benzinga · Feb 15, 2022

Tesla Shares Continue To Hold Strong In A Pattern: What's Next?

Tesla Inc. (NASDAQ: TSLA) shares are trading higher Monday. The stock is trading in a bullish reversal pattern and looks to have recently bounced off the 200-day support level. Piper Sandler maintained an Overweight rating on the stock and raised the price target to $1,350.

Benzinga · Feb 14, 2022

Why Are HubSpot Shares Trading Higher Today?

Analysts mainly hailed HubSpot Inc's (NYSE:HUBS) Q4 performance by raising their price targets on the stock. Mizuho analyst Siti Panigrahi raised the price target on HubSpot to $625 from $500 (16.92% upside) and kept a Buy rating on the shares.  The company reported strong results once again in Q4 on broad-based strength with a particular…

Benzinga · Feb 11, 2022